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Chronic or repeated exposure to stressful stimuli can result in several 
maladaptive consequences, including increased anxiety-like behaviors and altered 
peptide expression in brain structures involved in emotion. Among these structures, the 
bed nucleus of the stria terminalis (BNST) has been implicated in emotional behaviors 
as well as regulation of hypothalamic-pituitary-adrenal (HPA) axis activity. In rodents, 
chronic variate stress (CVS) has been shown to increase BNST pituitary adenylate 
cyclase activating polypeptide (PACAP) and its cognate PAC1 receptor transcript, and 
BNST PACAP signaling may mediate the maladaptive changes associated with chronic 
stress. In order to determine whether chronic stress would potentiate the behavioral 
and/or endocrine response to subthreshold BNST PACAP infusion, rats were exposed 
to a 7 day CVS paradigm previously shown to upregulate BNST PAC1 receptor 
transcripts; control rats were not stressed.  Twenty-four hours following the last 
stressor, stressed and control rats were bilaterally infused into the BNST with 0.5 µg 
PACAP. Startle response to intra-BNST PACAP infusion was assessed post-infusion in 
Experiment 1. In Experiments 2 and 3, blood was sampled via a tail nick 30 min 
following PACAP infusion to assess the corticosterone response to PACAP following 
CVS. We found an increase in startle amplitude and an increase in plasma 
corticosterone levels 30 minutes following BNST PACAP infusion only in rats that had 
been previously exposed to CVS. These results were likely mediated via PAC1 
receptors, as equimolar infusion of the VPAC1/2 receptor ligand vasoactive intestinal 
polypeptide (VIP) had no effect on plasma corticosterone levels. These results suggest 
that repeated exposure to stressors sensitizes the neural circuits underlying the 
behavioral and endocrine responses to BNST PACAP infusion and BNST 
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 CHAPTER 1: LITERATURE REVIEW 
1.1. Introduction 
Stressors activate several physiological and behavioral systems to promote 
homeostasis and survival. However, when stressor exposure becomes severe or 
repeated it places enhanced challenges on both physiological and psychological 
systems leading to the over activation of the physiological and behavioral systems 
typically recruited to reestablish homeostasis. Stressor exposure engages multiple 
response systems, including the sympathetic arm of the autonomic nervous systems, the 
hypothalamic—pituitary—adrenal (HPA) axis, and central nervous system (CNS) 
circuits responsible for fear and anxiety-like behavior. The sustained activation of these 
CNS nuclei in response to chronic stressor exposure has been argued to lead to the 
maladaptive morphological and functional changes that underlie fear- and anxiety-
related affective states, including altered peptide expression in the brain structures 
involved in emotion and increased anxiety-like behaviors (Hammack and May, 2014; 
Pego et al, 2008; Schulkin et al, 1998; Vyas et al, 2003). This has led to the idea that 
chronic stress encourages and produces stress-related disorders by increasing neuronal 
plasticity within stress-responsive nuclei. Indeed, Herman and colleagues suggest that 
the connection between limbic structures, affective disorders and HPA axis dysfunction 
is likely associated with impaired integration of hippocampal, amygdalar and/or 
prefrontal cortical information at one or more of the key subcortical regulatory nodes 
such as the bed nucleus of the stria terminalis (BNST) (Herman et al, 2005). 
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As mentioned, multiple forebrain limbic regions, including the hippocampus, 
medial prefrontal cortex (mPFC) and amygdala, regulate HPA axis in response to 
threatening stimuli. The nature of these stressors determines which stress-related 
regions are activated and the contribution of these regions to the stress response. For 
instance, the central amygdala (CeA) may be selectively tuned to interoceptive or 
visceral stimuli (reviewed in Herman et al, 2005). Additionally, processive or 
extroceptive stressors or threats with an emotional component requiring limbic 
structures activate peripheral stress responses and also stimulate central (behavioral) 
stress responding via extrahypothalamic projections to brain nuclei associated with fear 
and anxiety. Importantly, these regions consistently show maladaptive changes in 
affective disorders. This highlights a critical need for a better understanding of the 
pathways by which forebrain limbic structures regulate HPA axis responses as 
dysfunction among these structures and circuitry have been highly implicated in the 
etiology of several stress-related disorders. For example, posttraumatic stress disorder 
(PTSD) and depression both typically manifest HPA axis abnormalities (Choi et al, 
2007). For example, the hippocampus contains glucocorticoid receptors and plays a 
critical role in the regulation and termination of the HPA axis and has been suggested 
to be overactive in stress-related pathologies like hypercortisolemia (reviewed in 
Herman et al, 2005). In addition to the hippocampus, the medial prefrontal cortex 
(mPFC) is also a critical structure in regulating stress responses. Indeed, the mPFC has 
been shown to be critical for inhibiting the PVN; moreover, repeated stressor exposure 
has been shown to reduce mPFC neuron activity (Radley, Arias & Sawchenko, 
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2006; Radley and Sawchenko, 2011).  The disinhibition of the PVN likely plays a role 
in increased stress responding and stress-induced anxiogenic phenotypes. Additionally, 
lesions of different mPFC subregions have also been shown to differentially effect HPA 
axis output (Radley and Sawchenko, 2011). Finally, the amygdala has also been 
implicated in regulating HPA axis activity. Indeed, stimulation of the CeA excites the 
HPA axis (Vyas et al, 2003), and repeated stressor exposure increases dendritic 
arborization in the basolateral amygdala (BLA) (Herman et al, 2005).  
Importantly, almost every limbic region involved in regulating HPA activity 
does not project directly to the corticotropin releasing hormone (CRH) synthesizing 
PVN. Thus, information from these limbic and forebrain nuclei is relayed to the PVN 
via basal forebrain and hypothalamic structures, indicating that the effects on HPA axis 
are indirect and depend on the structural and functional integrity of these subcortical 
structures/relays. There is considerable opportunity for integration of limbic 
information at intermediary sites. Notably, the BNST receives projections from all of 
these limbic regions, and in turn, sends projections to the PVN (Dong and Swanson, 
2004; 2006). Moreover, there is considerable overlap between the inhibitory (e.g., the 
hippocampus and prelimbic cortex) and excitatory (e.g., medial amygdala) inputs 
within the BNST, suggesting that limbic information from stress-associated brain 
regions may be summated in the BNST, and then sent to the PVN (Herman et al, 2005). 
This likely role in integrating and relaying information from stress-associated regions 
coupled with the observation’s that BNST coordinates several behavioral response to 
stressor exposure (as will be discussed in more detail below), we and others have 
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argued that the BNST represents a critical site of confluence between stress responding 
and pathological affective states (Hammack and May, 2014), and the stress-induced 
morphological alteration in plasticity within the BNST likely underlie several stress-
related diseases. 
1.2. The Bed Nucleus of the Stria Terminalis (BNST) 
1.2.1. The BNST and Regulation of the Stress Response 
As discussed above, stressors result in the activation of several evolutionarily 
important homeostatic systems resulting in the mobilization of these adaptive 
responses, including the sympathetic arm of the autonomic nervous systems, the HPA 
axis, and the central nervous system CNS circuits responsible for fear and anxiety-like 
behavior. The BNST has been argued to modulate all three of the responses to 
sustained threats (Hammack and May, 2014; Herman et al, 2005; Radley and 
Sawchenko, 2011; Walker and Davis, 2008; Walker et al, 2003, 2009). For instance, 
the anterior and posterior BNST sub-regions receive projections from and project to the 
PVN to tightly regulate activity and mediate both the endocrine and autonomic 
response to stressors (Choi et al, 2007; Dunn, 1987; Radley, Gosselink and Sawchenko, 
2009).  
The BNST can be divided into cytoarchitecturally and anatomically distinct 
subregions. Within the anterior BNST, the dorsolateral region expresses CRH; within 
the posterior BNST, the principal nucleus contains GABAergic fibers which also 
project to the PVN (Dong and Swanson, 2004; 2006). HPA axis activity can be excited 
or inhibited, depending on which of these regions is targeted. Anterior or lateral 
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lesions decreases responses to stress and reduce PVN CRH mRNA; medial lesions have 
no effect; and posterior lesions increase resting CRH mRNA expression, suggesting 
that distinct nuclei of the BNST differentially regulate HPA axis activity (Choi et al, 
2007).                               
Furthermore, the BNST contains functionally distinct subregions that play 
opposing roles in integrating and processing limbic information in response to stress. 
For instance, posterior BNST lesions elevated plasma adrenocorticotropic hormone 
(ACTH) and corticosterone in response to acute stress, increased stress-induced PVN c-
fos, and elevated PVN CRH and vasopressin (AVP) mRNA expression; in contrast, 
anterior BNST lesions attenuated plasma CORT responses and decreased c-fos mRNA 
induction in the PVN but had no effect on CRH and AVP mRNA expression in the 
PVN, suggesting that posterior BNST nuclei inhibit HPA axis activity, whereas 
anteroventral nuclei excite the HPA axis (Choi et al, 2007).                              
1.2.2. The BNST and Regulation of Anxiety-like Behaviors 
The BNST plays a critical role in the development of anxiogenic behaviors in 
response to stressful stimuli and experience, acting as a sort of relay site for the 
multiple CNS pathways regulating PVN activity. Consequently, the BNST appears to 
play a crucial role in regulating the physiological and behavioral responses to stressor 
exposure. Support for this notion comes from studies showing that BNST activity is 
heavily implicated in mediating anxiety-like behavioral responding; complimenting 
these findings, pharmacological studies have shown anxiogenic agents to increase the 
expression of fos and other activation markers in the BNST (Singewald et al, 
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2003). More specifically, activation of the BNST has been argued to mediate anxiety-
like behavioral responding to diffuse, long-duration and/or unpredictable threats and 
may be responsible for mediating anxiety-like emotional states (Walker et al, 2003; 
2009; Waddell et al, 2006). Lee and Davis’ (1991) early lesion studies were the first to 
suggest that the BNST was critical for anxiety-like behavioral responses; whereas the 
CeA was more involved in fear-like responses. Consistent with this view, the BNST 
has been implicated in other anxiety-like behaviors including light-enhanced startle 
(Walker and Davis, 1997) as well as the stress-induced anxiogenic behaviors resulting 
from repeated stressor exposure (Hammack et al, 2004). Additionally, electrical 
stimulation of the anterolateral BNST produces many of the endocrine, cardiovascular 
and respiratory responses that are elicited by anxiogenic stimuli (Casada and Dafny, 
1991). Moreover, anxiogenic pharmacological agents such as yohimbine and m-
chlorophenylpiperazine (mCPP) increase BNST expression markers of neuronal 
activation (i.e., c-fos) and BNST inactivation blocks several anxiogenic behavioral 
responses (Singewald et al, 2003).  
The data implicating altered BNST structure and function in response to 
stressors are not limited to rodent models, as BNST activity has been correlated with 
anxiety-like behaviors in nonhuman primates as well as humans (Fox et al, 2008; Kalin 
et al, 2005; Somerville et al, 2010; Straube et al, 2007). For example, Kalin and 
colleagues (2005) showed that increased BNST activity in rhesus monkeys was 
positively correlated with individual differences in freezing behavior in response to eye 
contact (i.e., a threatening stimulus) with an intruder. In humans with arachnophobia, 
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BNST activation increases in responses to the anticipation of being shown an artificial 
spider (Straube et al, 2007). In aggregate, these findings contend that the BNST 
mediates anxiety-like responding when cues predict temporally distant threats (Waddell 
et al, 2006) and/or when behavioral responses need to be maintained for long durations 
(Walker and Davis, 2008). Thus, BNST-dependent responding drives a behavioral 
response distinct from fear and more representative of anxiety in humans, providing 
impetus for the idea that maladaptive BNST responding due to stress induced alteration 
within this structure, likely underlie some forms of anxiety disorders in humans 
(Hammack et al, 2010; 2012).  
1.2.3. Effects of Stress on BNST Circuitry 
As discussed above, altered BNST functioning is likely crucial for the etiology 
of several anxiety disorders associated with repeated stressor exposure (Hammack et al, 
2009; 2010; 2012; Pego et al, 2008; Schulkin et al, 1998; Vyas et al, 2003). This 
interpretation is supported by findings demonstrating that repeated exposure to stressors 
or stress hormones increases anxiety-like behavior which is correlated with enhanced 
neuroplasticity within the BNST, including increased neuronal peptide expression 
(Hammack et al, 2009; Roman et al, 2014; Stout et al, 2000). For example, Stout and 
colleagues (2000) showed that, within the BNST, elevations in CRH and 
neuroplasticity are associated with more anxiogenic behavior and anhedonia. 
Additional studies have shown that repeated exposure to stressors also enhances 
dendritic branching, length, and total BNST volume (Pego et al, 2008; Vyas et al, 
2003) and enhances excitatory synaptic transmission (Dumont et al, 2005). Given 
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that stressor exposure is a key component in the development of several affective 
disorders and that the BNST is a site of confluence between stress and emotion, these 
findings argue that stress-induced alterations in BNST neuronal function and plasticity 
likely underlie several forms of chronic anxiety in humans. Thus, chronic exposure to 
stressors physically alters BNST neurochemistry, morphology and physiology to 
facilitate function and promote increases in fear- and anxiety-like behaviors [reviewed 
in Hammack and May, 2014). These findings suggest that BNST neuropeptides with 
neurotrophic properties likely act as key mediators of the anxiogenic and maladaptive 
effects of chronic stress; however, the mechanisms of BNST signaling/plasticity in 
stress-induced anxiety remains to be elucidated.   
1.3. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) 
The findings discussed above suggest that alterations within the BNST result 
from increased neuroplasticity to produce the maladaptive consequences seen following 
chronic stress, and implicate neuropeptides with neurotrophic properties as key 
mediators of the anxiogenic and maladaptive effects of chronic stress. Several 
neurohormones and neuropeptides have been implicated in mediating these effects; 
perhaps none more than CRH. Yet, despite its key role in signaling and regulating fear- 
and anxiety-like behaviors, CRH lacks neurotrophic effects. Pituitary adenylate cyclase 
activating polypeptide (PACAP) and its cognate G-protein coupled PAC1 receptor have 
also been implicated in mediating stress- and anxiety-like responses and unlike CRH, 
the PACAP system exhibits neurotrophic properties and enhances neuronal excitability, 
and activation of the BNST PACAP system alone has been shown to be 
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anxiogenic. Moreover, PACAP and its PAC1 receptor are highly expressed in the 
BNST, are selectively upregulated in the BNST following chronic variate stress (CVS), 
exhibits neurotrophic properties and enhances neuronal excitability, and activation of 
the BNST PACAP system alone has been shown to be anxiogenic. Thus, the BNST 
PACAP system emerges as a prime mediator in regulating stress-induced anxiety 
(Hammack and May, 2014). 
1.3.1. The Role of PACAP in Stress and Anxiety 
 As mentioned, both PACAP and PAC1 have been implicated in regulating 
stress- and anxiety-like responses. Moreover, PACAP and PAC1 are highly expressed 
in the BNST and are selectively upregulated following chronic stress. For example, 
Hammack, May and colleagues (2009) exposed rats to a 7 day CVS paradigm where 
they received one of 5 different stressors each day for the 7 days (Table 1); 24 hours 
after the last stressors, 12 stress and fear-related brain regions were micropunched for 
quantitative RT-PCR in order to examine whether chronic stress could regulate PACAP 
expression in in brain regions implicated in stress-responding and/or anxiety-like 
behavior. Among the 12 neural regions examined, results showed that CVS selectively 
increased PACAP transcripts more than 10-fold in the dorsolateral BNST; a smaller but 
significant 2-fold increase in PACAP transcript was observed in the PVN [reviewed in 
Hammack et al, 2010). Among the remaining regions, including the CeA and 
basolateral amygdala (BLA), there was no difference in PACAP transcript levels 
between CVS and control tissue. CVS also induced an accompanying 2-fold increase in 




Additionally, the PACAP system exhibits neurotrophic properties and enhances 
neuronal excitability. Indeed, within the same tissue set, CVS augmented other stress-
related transcripts in the PVN and amygdala, some of which likely result from PACAP 
signaling. For example, following CVS the dlBNST showed a 3-fold and 2-fold 
increase in brain-derived neurotrophic factor (BDNF) and TrkB mRNA levels, 
respectively (Hammack et al, 2009). PACAP can stimulate neuronal BDNF and/or 
TrkB expression and function in several paradigms (Braas et al, 2007). Furthermore, 
Zink et al and colleagues have shown CNS BDNF expression to be diminished in 
PAC1 receptor knockout animals (Zink et al, 2004). Chronic stress results in long term 
structural and functional changes in dlBNST neuronal plasticity and BDNF function 
has been associated with anxiety-related behaviors, implicating PACAP-stimulated 
BDNF expression as one of the mechanisms underlying stress-induced plasticity within 
this structure. In support of this, our lab has that PACAP-treatment of dlBNST explants 
in serum-free cultures can increase expression of BDNF transcripts (Hammack and 
May, unpublished observation). Further corroboration comes from studies showing that 
following chronic stress other CNS nuclei, including the PVN and dorsal raphe nucleus 
(DRN), show increases in BDNF expression (Hammack et al, 2010). The 
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changes in BDNF expression within these regions may also reflect stress-mediated 
PACAP upregulation and signaling from the BNST as both structures are targets of 
BNST projections. These data suggest that among stress-related CNS nuclei, the 
dlBNST is a critical target of stress-induced plasticity, and this plasticity may represent 
a primary mechanism underlying anxiety disorders in humans.   
Further implicating the PACAP/PAC1 receptor system in stress responding, 
PACAP and PAC1 receptor null mice show reduced anxiety-like behavior and fear, 
including contextual fear conditioning (Girard et al, 2006; Hashimoto et al, 2001; Otto 
et al, 2001), diminished HPA axis activation and altered glucocorticoid responses after 
prolonged stressor exposure (Hashimoto et al, 2009; Stroth and Eiden, 2010).  
1.3.2. Effects of Intra-BNST PACAP on Stress and Anxiety 
Additionally, we have shown that intra-BNST PACAP infusion mimics, and 
intra-BNST PACAP receptor antagonism prevents, many of the consequences of 
chronic stress in the absence of any stressor.  
We have shown that bilateral intra-BNST infusions increased acoustic startle 
responding, were anxiogenic on the elevated plus maze (EPM), attenuated weight gain, 
and increased plasma corticosterone (Hammack et al, 2009; Kocho-Schellenberg et al, 
2014; Lezak et al, 2014; Roman et al, 2014). These effects were dose dependent, not 
due to ventricular leakage and not sexually dimorphic. Furthermore, these effects were 
likely mediated via BNST PAC1 receptors, as the effects were mimicked by intra-
BNST infusion of maxadilan (selective PAC1 receptor agonist) but not the VPAC1/2 
receptor ligand vasoactive intestinal polypeptide (VIP) (Roman et al, 2014).  
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Thus, these results show that BNST PACAP is sufficient to produce a stress and 
anxiety-like phenotype in rodents, but they don’t answer the question of whether 
endogenous BNST PACAP signaling participates in the behavioral and endocrine 
consequences of chronic stress. To address this rats were bilaterally cannulated and 
chronically delivered PACAP6-38 (a PAC1/VPAC2 receptor antagonist) during the 
week of CVS. Results revealed that PACAP6-38 was able to block the CVS-induced 
weight loss and anxiety-like behavior (Roman et al, 2014). Perhaps more importantly, 
the results showed that chronic stress sensitized the corticosterone response in reaction 
to a subsequent novel stress environment (i.e., open field maze) and acute BNST 
PACAP6-38 administration immediately before exposure to the novel environment 
attenuated the sensitized portion, specifically, of the corticosterone response to levels 
approximating those prior to stressor exposure (Roman et al, 2014). That is, PACAP 
antagonism blunted the corticosterone response when the animal had been previously 
exposed to chronic stress; but this attenuation was weakened in animals who had only 
been exposed to the acute stressor, suggesting that BNST PACAP signaling underlies 
the potentiated corticosterone response following chronic stress; but not acute stress. 
These results also corroborate Lezak et al. (2014) and further suggest that this system is 
recruited in response to long duration stressors and/or multiple stressor exposures 
(Stroth and Eiden, 2010). Taken together, the results implicate BNST PACAP signaling 
at PAC1 and/or VPAC2 receptors as a necessary system in mediating both the 
behavioral and endocrine consequences of chronic stressor exposure (Hammack et al, 
2009; Hashimoto et al, 2009; Roman et al, 2014; Stroth and Eiden, 2010). 
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1.3.3. BNST PACAP System in Human Affective Disorders 
The PACAP/PAC1 receptor system is highly conserved across species and is 
not just important in regulating stress responses in rodents, but has also been implicated 
in higher order primates. Indeed, in humans PACAP dysregulation has been associated 
with several psychopathologies, including post-traumatic stress disorder (PTSD). 
Elevated circulating PACAP levels and a PAC1 receptor gene (ADCYAP1R1) single-
nucleotide polymorphism (SNP) predict PTSD symptoms and diagnosis in women; 
methylation status was also associated with PTSD independent of gender (Ressler et al, 
2011). Importantly for the current study, a PAC1 receptor SNP has also been linked to 
startle behavior in male and female children (Jovanovic et al, 2013). These studies 
further implicate alterations in BNST PACAP signaling as a critical system mediating 
the stress-induced behaviors related to fear and anxiety.  
1.4. Aims of the Current Study 
The possible upregulation of BNST PAC1 receptors suggests that following 
CVS, the BNST may be more sensitive to PACAP release. To address this, the current 
experiments examined whether prior chronic stress could potentiate the behavioral 
and/or corticosterone response to a subthreshold intra-BNST PACAP infusion. We 
observed an increases in startle amplitude and plasma corticosterone levels following 
BNST PACAP infusion in stressed rats only. The effects were likely mediated via 
PAC1 receptors, as vasoactive intestinal polypeptide (VIP) infusion had no effect on 
plasma corticosterone levels. The current results suggest that repeated stressor exposure 
sensitizes BNST PACAP signaling, and this sensitization may play an important 
 14 
role in mediating the maladaptive consequences of stressor exposure, and may be an 
important target for the treatment of stress-related disease. 
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CHAPTER 2: CVS POTENTIATES THE STARTLE RESPONSE TO INTRA-
BNST PACAP INFUSION 
2.1. Introduction 
As mentioned above, we have previously examined the roles of BNST PACAP 
via direct injection of PACAP38 into the BNST and have shown that this elicits 
anxiety-like responses that mimic chronic stress in the absence of any stressor 
exposure; moreover intra-BNST PACAP receptor antagonism blocks the stress-induced 
consequences (Casada and Dafny, 1991; Roman et al, 2014; Stout et al, 2010; Walker 
and Davis, 1997). Specifically, bilateral intra-BNST infusions increased acoustic startle 
responding (Walker and Davis, 1997), was anxiogenic on the EPM (Casada and Dafny, 
1991) produced anorexia and weight loss (Roman et al, 2014), and increased plasma 
corticosterone (Stout et al, 2010). These effects were dose dependent, not due to 
ventricular leakage and not sexually dimorphic. Furthermore, these effects were likely 
mediated via BNST PAC1 receptors, as the effects were mimicked by intra-BNST 
infusion of maxadilan (selective PAC1 receptor agonist) but not the VPAC1/2 receptor 
ligand vasoactive intestinal polypeptide (VIP) (Roman et al, 2014). These results show 
that BNST PACAP is both necessary and sufficient to produce a stress and anxiety-like 
phenotype in rodents. Moreover, we have shown that BNST PACAP and PAC1 
receptor transcripts (but not VPAC1/2 transcripts) are upregulated following chronic 
stress. These results suggest that the PACAP system may be upregulated and thus more 
sensitive to PACAP release following chronic stress. To test this hypothesis, the current 
experiment examined whether prior chronic stress (i.e., CVS) could potentiate 




Adult male (200-225 g) Sprague-Dawley rats (n=36) were obtained from 
Charles River Laboratories (Canada). Rats were single-housed, maintained on a 12h 
light/dark cycle (lights on at 0700 h) and food and water were available ad libitum. Rats 
were allowed at least one week of habituation in their home cages prior to any 
experimentation. All procedures were approved by the Institutional Animal Care and 
Use Committee at the University of Vermont.  
2.2.2. Surgical Procedures 
For intra-BNST infusions, rats were anesthetized with isoflurane vapor (1.5—
3.5%), and secured in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) 
with “blunted” earbars. A midline head incision was made to expose the skull. After 
cleaning and sterilizing the skull, four burr holes were made, and four screws were 
inserted into the burr holes to provide skullcap stability. Two stainless steel guide 
cannulae (26 gauge, PlasticsOne, Roanoke, VA) were lowered at a 20º angle toward the 
midline to a point just above the oval BNST, using the following coordinates from 
Bregma in mm; AP = -0.1, ML = +3.9, and DV = -5.3 from the surface of the dura 
(Lezak et al, 2014). Once the guide cannulae were lowered into place, stylettes were 
inserted to ensure cannulae patency and a skullcap was constructed with dental cement 
to secure cannulae and stylettes in place. Immediately following surgery, rats were 
subcutaneously administered Lactated Ringer’s Solution to provide hydration, and 
Carprofen (5 mg/kg) (Pfizer) for analgesia before being returned to their home cages 
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for one week of post-surgery recovery. During recovery all rats were observed and 
weighed daily. Additionally, all rats received a second subcutaneous injection of 
Carprofen (5 mg/kg) 24h following surgery.   
2.2.3. Chronic Variate Stress (CVS) 
Following postsurgery recovery, rats were randomly assigned to control or 
chronic variate stress (CVS) groups. Control group rats were handled and weighed 
daily, and housed in their home cages until infusion. The chronically stressed group of 
rats underwent a CVS paradigm in which rats were exposed to one of 5 different 
stressors (oscillation, forced swim, footshock, restraint and pedestal) each day for 7 
days, as previously described in detail (Hammack et al, 2009). All rats were exposed to 
the same order of stressors for the same duration (Error! Reference source not 
found.).  
For the oscillation stressor, rats were placed inside a plastic chamber 28 cm x 17 
cm x 13 cm (L x W x H), that was secured to a clinical rotator and oscillated at low to 
medium speed for 30 min. 
For forced swim, rats were placed in a cylindrical container 29 cm x 37 cm (D x 
H) that was filled with room temperature water to a depth that prevented the rats tail 
from touching the bottom. After 5 mins of monitored swimming, rats were placed in a 
holding chamber for 30 min prior to being returned to their homecage.  
Footshock involved placing the rats inside a Plexiglas conditioning chamber 
(Med Associates, St. Albans, VT) 30 cm x 25 cm x 35 cm (L x W x H). After a 5 min 
acclimation period, two 1.0 mA 5 s scrambled footshocks were delivered 
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through the grid floor with a 5 minute inter-trial interval. Following the second shock, 
rats remained in the chamber an additional 5 min and were then returned to their 
homecage. 
Restraint consisted of placing each rat into a cylindrical restraining device 9 cm 
x 15 cm (D x H) for 60 min. Following the 60 min, rats were returned to their 
homecage. 
For pedestal, rats were placed on an elevated platform 20 cm x 20 cm (L x W) 
that was 60 cm from the floor. Rats remained on the pedestal for 30 min and were then 
returned to the homecage. 
2.2.4. Startle Apparatus 
Each acoustic startle stabilimeter chamber consisted of an 8 cm x 15 cm x 15 
cm acrylic and wire-mesh cage with four stainless steel floor bars spaced 18 mm apart. 
The cage was suspended between compression springs within an acrylic frame located 
within a 90 cm x 70 cm x 70 cm ventilated sound-attenuating cubical. Chamber 
movement resulted in the displacement of an accelerometer (Model U321AO2; PCB 
Piezotronics, Depew, NY), which was fixed to the bottom of the cage; the resulting 
voltage was proportional to the velocity of displacement. The analog output of the 
accelerometer was amplified (PCB Piezotronics, Model 483B21) and digitized on a 
scale of 0—10 V by an InstruNET analog to digital converter (GW Instruments, Model 
100B; Somerville, MA) interfaced to a Macintosh G3 computer. Startle amplitude was 
defined as the maximal peak-to-trough voltage during the first 200 ms after the 
stimulus onset. Startle responses were evoked by 50 ms white-noise bursts 
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generated by a Macintosh G3 computer sound file, amplified by a Radio Shack 
Amplifier (100 W; Model MPA-200; Tandy, Fort Worth, TX), and delivered through a 
high frequency speaker (Radio Shack Super-Tweeter; Tandy, Fort Worth, TX) located 
5 cm from the back of each cage.  
2.2.5. Cannulae Verification 
Upon completion of each experiment, rats were anesthetized with sodium 
pentobarbital and perfused transcardially with 0.9% saline containing 0.1% heparin 
(Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed and 
postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat 
and mounted on subbed slides for staining with cresyl violet. Following staining, slides 
were coverslipped and cannulae placements were verified using a 4x Nikon Objective 
on an Olympus light microscope.  
2.2.6. Statistics  
Statistical analyses were completed using SPSS version 21 (IBM Software, 
Armonk, NY) and all graphical representations were completed using GraphPad Prism 
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for 
BNST cannulation experiments if the cannulae fell outside the histological boundary of 
the BNST. Additionally, rats were eliminated if their startle amplitude was more than 
two standard deviations away from the treatment mean. Two-way ANOVA or Repeated 
Measures ANOVA was used to calculate overall group differences and interactions 
followed by Tukey’s post hoc comparisons. 
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2.2.7. Experimental Procedure 
Rats were implanted bilaterally with guide cannulae aimed at the dorsal BNST. 
Postoperative care was completed as described above. Following recovery, rats were 
administered 2 baseline startle test on consecutive days in which they were placed into 
the startle chambers and allowed a 5 min acclimation to the chamber. The response to 
33 randomized noise burst (described above) that varied in intensity (95, 100, or 
105dB) with a 30 s intertrial interval was then determined as the average response 
across the session. After each baseline startle testing session, rats were returned to their 
home cages. Based on the average startle across all 3 noise burst intensities for the 2 
days of baseline startle rats were “matched” on their average startle to 1 of 4 
experimental groups: control/PACAP (n=10), control/vehicle (n=6), CVS/PACAP 
(n=10), or CVS/vehicle (n=8), so that baseline startle amplitude did not differ between 
groups. For the subsequent 7 days, stressed rats were treated with CVS as described 
above; control rats were handled and weighed but not otherwise stressed. On the 8th 
day, prior to infusions, all rats were returned to the startle chambers and received a 3rd 
startle test that was identical to the prior baseline testing sessions. Immediately after 
this third test, rats were removed from the startle chamber and bilaterally infused with 
0.5 µl 0.05% bovine serum albumin (BSA)/vehicle (Santa Cruz Biotech., Santa Cruz, 
CA) or 0.5 µg PACAP38 (American Peptide Co., Sunnyvale, CA) in 0.5 µl BSA 
vehicle. The PACAP dose was chosen as we have previously shown it to be below the 
threshold required to produce anxiety-like behavior and corticosterone release when 
infused into the BNST (Hammack et al, 2009; Lezak et al, 2014). Infusions were 
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completed in the colony room under light restraint. For each infusion: the stylette was 
removed and an internal cannula that extended 1 mm beyond the end of the guide 
cannula was inserted. Injections were completed using a 10 µl Hamilton syringe 
connected to the internal cannula with PE50 plastic tubing. A volume of 0.5 µl was 
infused into the BNST over the course of 60 s. Following infusion, the internal cannula 
was left in place for an additional 60 s to allow for diffusion of the drug away from the 
infusion site. The internal cannula was then removed, and an identical infusion was 
completed for the opposite side. After infusions rats were returned to the home cage for 
15 minutes until subsequent testing.  
Fifteen minutes after infusion, the rats were returned to the startle chamber and 
after a 5 min acclimation period, rats were administered a 4th and final startle test that 
consisted of 72 startle stimuli that varied in intensity. After the final startle test, rats 
were returned to their home cages.  
2.3. Results 
The BNST of adult male rats was bilaterally cannulated and a subthreshold dose 
of PACAP was infused into the BNST of chronically stressed and control rats 15 min 
prior to startle testing. BNST injection sites are depicted in Figure 1. Based on histology, 
no animals were excluded from analysis; however, outlier analyses revealed 2 subjects 
with startle amplitudes more than 2 standard deviations outside the treatment mean, and 
thus these subjects were excluded from further analyses. 
 22 
 
Figure 1: Experiment 1 BNST PACAP infusion sites. Placements of cannulae tips for rats that 
received 0.5 µg PACAP38 (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug 
infusion depicted on coronal sections as a distance (mm) from Bregma (Histological figures modified 
from Paxinos and Watson, 2009). 
As can be seen in Figure 2, a typically subthreshold dose of PACAP38 bilaterally 
infused into the BNST increased startle amplitude later in the startle test session, but only 
in rats previously exposed to the CVS paradigm.  
 
Figure 2: CVS Potentiates the Behavioral Response to Intra-BNST PACAP Infusion. Intra-BNST 
PACAP infusion increased startle amplitude but only in rats previously exposed to CVS. Data 
represent startle amplitude after infusion as a percent of pre-infusion Pretest startle. Significant 3-
way Blocks x CVS x PACAP interaction, p < 0.01. The effects of PACAP vary across test blocks.   
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The data are presented as startle amplitude across the 12 3 minute blocks (i.e., 6 
30s startle events) of test post-infusion as a percent of the last 9 minutes (18 startle 
events) of preinfusion/pretest startle. Repeated Measures Analysis of Variance revealed a 
significant 3-way Blocks x CVS x PACAP interaction across all test bins, F (13, 403) = 
2.084, p = 0.01. However, there were no statistically significant main effects of CVS or 
PACAP, suggesting that the effects of PACAP vary across test blocks depending on 
whether the animal was chronically stressed or not.   
To further investigate the effects of PACAP across test blocks, the 12 test blocks 
were broken into thirds and assessed with two-way ANOVA’s (Figure 3). CVS nor 
PACAP had effects on startle amplitude in the first or second thirds of the test session 
(Figure 3A and B). In the last third of test (i.e., blocks 9-12), however, intra-BNST 
PACAP increased startle amplitude, but only in those rats exposed to CVS (Figure 3C). 
Two-way ANOVA revealed a significant CVS x PACAP interaction, F (1, 29) = 5.156, p 
= 0.03, but no statistically significant main effects of CVS or PACAP, again suggesting 
that stress potentiates the behavioral response to intra-BNST PACAP infusion.  
 
Figure 3: CVS nor PACAP had an effect on startle during the first (A) or second third (B) of the test 
session. (C) Intra-BNST PACAP increased startle amplitude only during the last third of the test 
session, and only in rats exposed to CVS, suggesting that stress potentiates the behavioral response to 
BNST PACAP infusion. Data represents mean +/- SEM. *Significantly different at p < 0.05. 
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2.4. Discussion 
Results from experiment 1 showed that only those rats that had been previously 
exposed to CVS exhibited an increase in startle amplitude at approximately 30 minutes 
after a normally subthreshold dose (0.5 µg) of intra-BNST PACAP. These results 
suggest that CVS induces plasticity within the BNST, making it more sensitive to 
PACAP, resulting in a potentiated behavioral response. Because we have previously 
shown these effects to be mediated by PAC1 receptors, and PAC1 receptor transcripts 
are increased by CVS, this sensitivity is likely mediated via PAC1 receptor activation; 
however, this was not yet confirmed. The current results also further suggest that stress-
induced sensitization in behavioral responses to PACAP likely plays a critical role in 
mediating the consequences of repeated stressor exposure. 
In the current experiment, the potentiated startle effect was not observed until 
later in the startle test session at approximately 30 minutes post PACAP infusion. 
Walker, Davis and colleagues have shown a similar delayed onset in CRH-enhanced 
startle, with effects not becoming evident until 20 minutes after intra-BNST CRH 
infusion (Walker et al, 2003). They have argued that fear-potentiated startle represents 
conditioned fear; whereas CRH-enhanced startle more closely represents anxiety as it 
shows a gradual onset and prolonged effects (Lee and Davis, 1997; Walker et al, 2003). 
Thus, the current results suggest that intra-BNST PACAP infusion, like intra-BNST 
CRH infusion, also produces a sustained and long-lasting change in behavior and a 
persistent anxiety-like state, as opposed to a fear state, and this anxiety-like behavioral 
response becomes potentiated following chronic stress. This interpretation is 
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further supported by Hammack et al, who has shown a similar time effect with the 
initial PACAP-induced anxiogenic effects increasing over the test sessions as well as a 
long-lasting (7 day) intra-BNST PACAP effect on light-enhanced startle, which like 
CRH-enhanced startle is argued to be more akin to anxiety (Hammack et al, 2009; 
Walker et al, 2003). Thus, although we have shown the greatest effects of intra-BNST 
PACAP on the stress (i.e., corticosterone) response at 30 minutes post PACAP 
infusion, the current study in aggregate with previous studies suggest that the initial 
activation of these PACAP and/or CRH neuroendocrine systems (i.e., long-duration 
stimuli) is enough to activate and produce a delayed, yet long-lasting potentiation in 
anxiety-like behavior, representing a PACAP induced neuroplasticity within the BNST, 
resulting in a long-term increase in anxiety-like behavior.  
There is a close relationship between the PACAP and CRH systems; especially 
among PVN and BNST neurons where PACAPergic fibers densely innervate CRH 
neurons (Kozicz et al, 1997; Missig et al, 2014). Notably, chronic stress has been 
shown to increase BNST CRH, mediating an increased anxiety-like behavioral 
phenotype (Fox et al, 2008). Furthermore, we have shown increased PACAP 
expression within these same brain regions following chronic stress, and intra-BNST 
PACAP infusion (current study) as well as intra-BNST CRH enhanced baseline startle. 
Together these results suggest that PACAP may mediate increased plasticity and 
function specifically within BNST CRH neurons. It could be argued that PAC1 
receptors upregulate specifically on BNST CRH neurons. Future studies are needed to 
examine this possibility but given the advancements in genetics and viral 
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vectors, this hypothesis could be examined. For instance, a cre-animal genetically 
modified to express GFP in CRH neurons could be double-labeled with a PAC1 
receptor antibody; if coexpression increased following chronic stress, this would 
suggest that the stress-induced changes in plasticity are mediated via upregulation of 
PAC1 receptors on BNST CRH neurons. 
The results from Roman et al. (2014) suggest that BNST PACAP/PAC1 
receptor signaling mechanisms may coordinate the behavioral and endocrine 
consequences of stress. Furthermore, chronic injection of stress levels of corticosterone 
fails to produce the chronic stress-induced increases in PACAP transcript (Lezak et al, 
2014). These results suggest that the BNST PACAP system likely sits upstream of the 
corticosterone system as well as the other physiological outputs of stressor exposure. 
The current study further implicates the BNST PACAP system as an upstream mediator 
of the corticosterone as intra-BNST PACAP infusion was also able drive an enhanced 
startle response. Furthermore, taken with the circuitry laid out by Walker, Davis and 
colleagues (Lee and Davis, 1997; Walker and Davis, 1997; Walker et al, 2003), the 
results suggest that PAC1 receptors could be upregulated on CRH neurons in the 
BNST, leading to stronger activation of these CRH neurons projecting to the nucleus 
reticularis pontis caudalis (Lee and Davis, 1997), resulting in the enhanced anxiety-like 
startle response. These results also further implicate the BNST PACAP system as a 
good potential therapeutic target in stress and anxiety-related pathologies like PTSD.      
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CHAPTER 3: CVS POTENTIATES THE ENDOCRINE RESPONSE TO INTRA-
BNST PACAP INFUSION 
3.1. Introduction 
Experiment 1 determined that intra-BNST infusion of a subthreshold dose of 
PACAP38 following CVS does produce an anxious phenotype, as measured by an 
increase in startle amplitude. Given that the behavioral response to PACAP was 
sensitized following chronic stress, the corticosterone response to PACAP may also be 
potentiated. Thus, experiment 2 examined the effects of a subthreshold dose of 




Adult male (200-225 g) Sprague-Dawley rats (n=39) were obtained from 
Charles River Laboratories (Canada). Rats were single-housed, maintained on a 12h 
light/dark cycle (lights on at 0700 h) and food and water were available ad libitum. Rats 
were allowed at least one week of habituation in their home cages prior to any 
experimentation. All procedures were approved by the Institutional Animal Care and 
Use Committee at the University of Vermont.  
3.2.2. Surgical Procedures 




3.2.3. Chronic Variate Stress (CVS) 
Following one week of postoperative recovery, rats were randomly assigned by 
weight into control (n=21) or CVS (n=18) groups. Control rats were handled and 
weighed daily, and housed in their home cages until infusion; stressed rats underwent the 
7 days of CVS described above. Twenty-four hours after the last stressor, animals were 
weighed and bilaterally infused into the BNST with vehicle or PACAP38 as described 
above.  
3.2.4. Corticosterone Enzyme-Linked Immunoassay 
Following collection of plasma from tail nick blood samples, a corticosterone 
enzyme-linked immunoassay (CORT EIA, Enzo Life Sciences, Farmingdale, NY) was 
used to determine plasma corticosterone levels. Plasma samples were first diluted 1:30 
and heated in a 75ºC water bath for approximately one hour to denature corticosterone 
binding globulin (Buck et al, 2011). The interassay coefficient of variation was X.X% 
and the sensitivity of the assay was 27.0 pg/ml.  
3.2.5. Cannulae Verification 
Using procedures identical to experiment 1, rats were anesthetized with sodium 
pentobarbital and perfused transcardially with 0.9% saline containing 0.1% heparin 
(Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed and 
postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat and 
mounted on subbed slides for staining with cresyl violet. Following staining, slides were 
coverslipped and cannulae placements were verified using a 4x Nikon Objective on an 
Olympus light microscope.  
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3.2.6. Statistics  
Statistical analyses were completed using SPSS version 21 (IBM Software, 
Armonk, NY) and all graphical representations were completed using GraphPad Prism 
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for 
BNST cannulation experiments if cannulae placement fell outside the histological 
boundary of the BNST. Additionally, rats were eliminated if their mean corticosterone 
response was more than two standard deviations away from the treatment mean. Two-
way ANOVA was used to calculate overall group differences and interactions followed 
by Tukey’s post hoc comparisons. Some comparisons were made using t-test.  
3.2.7. Experimental Procedure 
Male rats were bilaterally cannulated with guide cannulae aimed at the oval 
BNST as described above. Following one week of postoperative recovery, rats were 
matched by weight into control (n=21) or CVS (n=18) groups. Control rats were handled 
and weighed daily, and housed in their home cages until infusion; stressed rats underwent 
the 7 days of CVS described above. Twenty-four hours after the last stressor, animals 
were weighed and bilaterally infused into the BNST with vehicle or PACAP38 as 
described above. Following bilateral infusion, the rat was returned to the home cage and 
remained in the colony room for 30 minutes until blood sampling.  
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While blood sampling was conducted in a nearby room the time required to 
transport animals and obtain the blood sample was less than 3 min, in order to avoid 
contamination of the sample with the increase in corticosterone release associated with 
cage removal. Thirty minutes post-infusion, blood was collected via a small tail nick with 
the rat under light restraint. This time point was chosen because we have previously 
shown increased corticosterone following intra-BNST PACAP (1µg) at 30-60 min post 
infusion (Lezak et al, 2014). The sample was immediately placed into a refrigerated 
centrifuge and spun between 2000 and 4000 rpm for 15-20 minutes to separate the 
plasma. Plasma was then collected and stored at –20 ºC until corticosterone quantification 
via a CORT EIA (see above). 
3.3. Results 
Experiment 2 examined the effects of a subthreshold dose of PACAP38 following 
CVS, on the corticosterone response. Using procedures similar to experiment 1, adult 
male rats were bilaterally cannulated and infused with a subthreshold dose of PACAP38 
following CVS, and plasma corticosterone levels were assessed. BNST injection sites are 
depicted in Figure 4. No subjects were removed for cannulae placements, however, 
outlier analysis revealed a single rat with unusually high plasma corticosterone (greater 
than 2 SD’s above the mean) who was excluded from further analyses. 
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Figure 4: Experiment 2 BNST PACAP infusion sites. Cannulae placements for rats that received 0.5 
µg PACAP38 (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug infusion depicted 
on coronal sections as a distance (mm) from Bregma (Histological figures modified from Paxinos and 
Watson, 2009). 
There was an increase in plasma corticosterone 30 minutes after intra-BNST 
PACAP infusion, but only in the rats previously exposed to CVS (Figure 5). Two-way 
ANOVA revealed a significant main effect of CVS, F (1, 37) = 13.05, p < 0.001, and a 
significant main effect of PACAP, F (1, 37) = 7.016, p = 0.01, on plasma corticosterone 
levels. Additionally, results revealed a trending interaction between CVS and PACAP on 
plasma corticosterone levels, F (1, 37) = 3.401, p = 0.07. Further examination of the 
trending interaction with subsequent t-test revealed significant differences in plasma 
corticosterone levels between the CVS/PACAP and CVS/Vehicle groups, t (17) = 3.53, p 
< 0.01 as well as the CVS/PACAP and Control/PACAP groups, t (17) = 3.53, p < 0.01. 
There was no significant difference in corticosterone levels between the Control/PACAP 
and Control/Vehicle groups, t (20) = 0.54, ns.  
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The results of the t-tests further argue the interaction between CVS and PACAP, 
suggesting that, like the behavioral response in Experiment 1, CVS also sensitizes the 
corticosterone response to intra-BNST PACAP infusion. 
 
Figure 5: CVS potentiates the corticosterone response to intra-BNST PACAP infusion. Plasma 
corticosterone was elevated 30 m after BNST PACAP infusion, but only in rats exposed to CVS, 
suggesting that stress also potentiates the endocrine response to intra-BNST PACAP infusion. Data 
represents mean +/- SEM. *Significantly different at p < 0.05 
3.4. Discussion 
In experiment 2, rats that had been previously exposed to CVS exhibited an 
increase in plasma corticosterone at 30 minutes post PACAP infusion as compared to 
non-stressed/control PACAP-infused rats. These results suggest that CVS is capable of 
not only potentiating the behavioral response to subthreshold intra-BNST PACAP 
infusion, but also the corticosterone response, replicating and extending previous 
findings implicating increased plasticity within the BNST, resulting in a sensitizes 
response to PACAP signaling. Thus, like experiment 1, experiment 2 further supports a 
role for stress-induced plasticity within the BNST, sensitizing this arm of the stress 
response to subsequent PACAP release and signaling. This sensitized BNST PACAP 
system likely represents one of the primary mediators of the negative consequences of 
repeated stressor exposure.   
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We know that CRH and PACAP are both are highly expressed in close 
proximity, but form distinct populations within the oval nucleus of the BNST (Kozicz 
et al, 1997; Missig et al, 2014), and chronic stress increases endogenous PACAP 
expression selectively in the oval nucleus in patterns that are distinct from CRH 
patterns (Hammack and May, 20014; Roman et al, 2014). Thus, it seems likely that 
these distinct populations could interact within the dBNST to drive HPA axis activity 
and behavioral responding to stressful or emotional stimuli. Furthermore, the current 
study and others suggest that intra-BNST PACAP can mimic and intra-BNST PACAP 
receptor antagonism prevents, many of the consequences of chronic stress, including 
HPA axis responsiveness and increased levels of corticosterone (Lezak et al, 2014; 
Roman et al, 2014). These findings in aggregate suggest a critical BNST to PVN 
circuitry that is responsible for driving the enhanced corticosterone response. Thus, it 
seems likely that chronic stress produces an increase in endogenous PACAP expression 
and levels within the oval nucleus. This likely results in an upregulation of PAC1 
receptors within the oval nucleus which could activate local oval nucleus CRH neurons 
to drive downstream corticosterone producing neurons in the PVN and a subsequent 
increase in corticosterone facilitating the stress response and anxiety-related behavior. 
Again, both CRH and PACAP are highly expressed in the dBNST, and the 
interaction between these distinct populations are thought to drive PVN activity and 
subsequent corticosterone responses. However, it remains unclear as to whether the 
dBNST projects directly to the PVN to drive this response. Instead studies suggest that 
dBNST plays more of an integration and regulatory function, while the 
 34 
ventrolateral BNST (vlBNST) sends direct projections to the PVN, driving its activity 
(Dong and Swanson, 2003; 2006). That is, stress acts on PACAPergic fibers and CRH 
neurons in the dBNST, where the information is integrated; this is then sent to the 
vlBNST, possibly via known dBNST-vlBNST GABAergic projections or possibly 
CRH or PACAPergic projections from dBNST. Within vlBNST, excitatory CRH, 
inhibitory GABA and possibly PACAP neurons project to and act on PACAP and/or 
CRH neurons within the PVN to produce the corticosterone response. Thus, dBNST 
regulates vlBNST, which then projects and drives PVN activity to produce the 
corticosterone response. 
Despite the significant interaction and differences among the groups in 
experiment 2, the control animals still displayed unusually high levels of 
corticosterone. Given that this hormone is released in response to a stressor in order to 
bring the animal back into homeostasis, and that no other stressors were presented 
between the injection and blood collection, it seems like that the current studies 
injection procedures were inherently stressful. Indeed, we anticipated this and took 
precautions to minimize the natural stress response, however, it appears that the 
animals still experienced a stressful experience. This is unlikely to account for the 
differences observed among groups however, as experimental animals were exposed to 
the same infusion procedures controlling for this possibility. 
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CHAPTER 4: INTRA-BNST VIP INFUSION HAS NO EFFECT ON 
CIRCULATING CORTICOSTERONE 
4.1. Introduction 
Experiment 1 determined that intra-BNST infusion of a subthreshold dose of 
PACAP38 following CVS results in an anxious phenotype, and experiment 2 to showed 
that the endocrine response to PACAP was also potentiated following stress. Experiment 
3 was designed to determine whether this sensitized response was mediated via PAC1 
receptors. Recall that PACAP binds to PAC1R’s and VPAC1&2 R’s with similar 
affinities, whereas VIP binds selectively to VPAC receptors, but not PAC1 receptors. 
Thus, experiment 3 was designed to determine whether CVS could potentiate the 
response to BNST VIP infusion.   
4.2. Methods 
4.2.1. Animals 
Adult male (200-225 g) Sprague-Dawley rats (n=33) were obtained from Charles 
River Laboratories (Canada). Rats were single-housed, maintained on a 12h light/dark 
cycle (lights on at 0700 h) and food and water were available ad libitum. Rats were 
allowed at least one week of habituation in their home cages prior to any 
experimentation. All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Vermont.  
4.2.2. Surgical Procedures 
All surgical and post-operative producers were identical to those used in 
experiment 1 and 2. 
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4.2.3. Chronic Variate Stress (CVS) 
Following one week of postoperative recovery, rats were randomly matched by 
weight into control (n=16) or CVS (n=17) groups. Control rats were handled and 
weighed daily, and housed in their home cages until infusion; stressed rats underwent the 
7 days of CVS described above.  
4.2.4. Corticosterone Enzyme-Linked Immunoassay 
Following collection of plasma from tail nick blood samples, a corticosterone 
enzyme-linked immunoassay (CORT EIA, Enzo Life Sciences, Farmingdale, NY) was 
used to determine plasma corticosterone levels. Plasma samples were first diluted 1:30 
and heated in a 75ºC water bath for approximately one hour to denature corticosterone 
binding globulin (Buck et al, 2011). The interassay coefficient of variation was X.X% 
and the sensitivity of the assay was 27.0 pg/ml.  
4.2.5. Cannulae Verification 
Using procedures identical to experiment 1 and 2, rats were anesthetized with 
sodium pentobarbital and perfused transcardially with 0.9% saline containing 0.1% 
heparin (Sagent, Schaumburg, IL) followed by 10% formalin. Brains were then removed 
and postfixed for 24h in 10% formalin. Fixed tissue was sectioned at 60 µm on a cryostat 
and mounted on subbed slides for staining with cresyl violet. Following staining, slides 
were coverslipped and cannulae placements were verified using a 4x Nikon Objective on 
an Olympus light microscope.  
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4.2.6. Statistics  
Statistical analyses were completed using SPSS version 21 (IBM Software, 
Armonk, NY) and all graphical representations were completed using GraphPad Prism 
version 6 (GraphPad Software, San Diego, CA). Rats were eliminated from analysis for 
BNST cannulation experiments if cannulae placement fell outside the histological 
boundary of the BNST. Additionally, rats were eliminated if their mean corticosterone 
response was more than two standard deviations away from the treatment mean. Two-
way ANOVA was used to calculate overall group differences and interactions followed 
by Tukey’s post hoc comparisons. Some comparisons were made using t-test.  
4.2.7. Experimental Procedure 
All procedures were identical to those used in experiment 2. Twenty-four hours 
after the last stressor, animals were weighed and bilaterally infused into the BNST with 
0.5 µl 0.05% BSA/vehicle (Santa Cruz Biotech., Santa Cruz, CA) or 0.73 µg VIP 
(American Peptide Co., Sunnyvale, CA) in 1.0 µl BSA vehicle. The VIP dose was chosen 
as it was determined to be equimolar (221µm) to the PACAP dose used in experiments 1 
and 2, thereby limiting potential effects due to inherent pharmacodynamic differences in 
the ligands used. Following bilateral infusion, the rat was returned to the home cage and 
remained in the colony room for 30 minutes until blood sampling.  
While blood sampling was conducted in a nearby room the time required to 
transport animals and obtain the blood sample was less than 3 min, in order to avoid 
contamination of the sample with the increase in corticosterone release associated with 
cage removal. Thirty minutes post-infusion, blood was collected via a small tail nick 
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with the rat under light restraint. This time point was chosen because we have previously 
shown increased corticosterone following intra-BNST PACAP (1µg) at 30-60 min post 
infusion (Lezak et al, 2014). The sample was immediately placed into a refrigerated 
centrifuge and spun between 2000 and 4000 rpm for 15-20 minutes to separate the 
plasma. Plasma was then collected and stored at –20 ºC until corticosterone quantification 
via a CORT EIA (see above). 
4.3. Results 
Using procedures identical to that of experiment 2, adult male rats were 
bilaterally cannulated (Figure 6) and infused with VIP following CVS. No subjects were 
removed from the analyses based on cannulae placements or outlier analysis. 
 
Figure 6: Experiment 3 BNST VIP infusion sites. Cannulae placements for rats that received 0.7 µg 
VIP (221µM) (0.5 µl/side) intra-BNST infusions. Open dots represent site(s) of drug infusion depicted 






Following infusion of VIP into the BNST, plasma corticosterone levels were 
assessed.  Two-way Analysis of Variance revealed no effect of CVS, F (1, 29) = 0.04, ns, 
and no effect of VIP, F (1, 29) = 0.001, ns, on plasma corticosterone levels (Figure 7). 
Furthermore, there was no significant interaction between CVS and VIP on 
corticosterone levels, F (1, 29) = 2.218, ns, suggesting that the potentiated endocrine 
response observed in experiment 2 was mediated via PAC1 receptors, not VPAC 
receptors. 
 
Figure 7: Intra-BNST VIP infusion has no effect on the corticosterone response following CVS. 
Intra-BNST VIP that was equimolar to the PACAP38 used in experiments 1 and 2 produced no 
effect on plasma corticosterone levels following CVS, suggesting that the sensitized corticosterone 
response observed in Experiment 2 was mediated via PAC1R’s. Data represents mean +/- SEM. 
4.4. Discussion 
Results from experiments 1 and 2 provided evidenced for stress-induced 
plasticity and alterations in PACAP signaling within the BNST promoting maladaptive 
behavioral and endocrine responses. However, the results did not determine which 
receptors: PAC or VPAC1/2 were responsible for mediating these responses.   
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Recall that PACAP effects can be mediated via 3 receptor subtypes. Of these 
receptor subtypes, the PAC1 receptor is selective for PACAP while the VPAC1/2 
receptors are demonstrate near equal affinities for PACAP and VIP. Thus, if the effects 
are mediated via PAC1 receptors then VIP infusion should have no effect on the 
potentiated responses. 
 Experiment 3 confirmed this hypothesis and showed that equimolar infusion 
(0.7 µg) of the VPAC1/2 agonist VIP had no effect on plasma corticosterone levels, 
even in stressed rats. Thus, the results seen in experiments 1 and 2 are appear to be 
driven via BNST PACAP/PAC1 receptor signaling.  
These results are consistent with our previous finding (reviewed in Hammack 
and May, 2014) showing that it is PACAP/PAC1, not VPAC, activation and signaling 
which is responsible for the stress-induced changes in physiology and behavior.  
It should be noted that VIP is found in the oval nucleus of the BNST and could 
have some role in the stressed induced plasticity. This doesn’t seem likely, as studies 
have shown that PACAP and VIP display differential expression patterns; moreover, 
the 2 distinct systems appear non-compensatory in K.O. studies (Girard et al, 2006) 




CHAPTER 5: GENERAL DISCUSSION 
 The upregulation of BNST PAC1 receptors suggests that following CVS, the 
BNST may be more sensitive to PACAP release and may be one of the critical 
mechanism involved in mediating the maladaptive consequences of repeated stressor 
exposure. The current set of experiments were designed to examine whether chronic 
stress produces these negative consequences by altering BNST plasticity via a 
potentiated PACAP system. Specifically, the experiments examined whether CVS 
could potentiate the behavioral and/or corticosterone response to a subthreshold intra-
BNST PACAP infusion.  
Results from experiment 1 showed a significant increases in startle amplitude at 
approximately 30 minutes after a normally subthreshold dose (0.5 µg) of intra-BNST 
PACAP; however these results were limited to those animals exposed to CVS. 
Correspondingly, experiment 2 showed a significant increase in plasma corticosterone 
levels at 30 minutes post subthreshold PACAP as compared to non-stressed PACAP-
infused rats following BNST PACAP infusion; again, these results were only observed 
in those rats subjected to chronic stress. In addition, experiment 3 provided evidence 
that these sensitized responses were mediated via PAC1 receptors, as equimolar 
infusion (0.7 µg) of the VPAC1/2 agonist VIP had no effect on plasma corticosterone 
levels, even in stressed rats. The current results provide evidence for a potentiated 
BNST PACAP system and PACAP-signaling following chronic stress. Furthermore, 
the results provide a mechanism through which stress, via altered/sensitized 
neurotrophic peptide systems and subsequent modification and plasticity 
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within the BNST may promote the maladaptive consequences of stressor exposure. 
Additionally, the current study further argues that this system may be an important 
target for the treatment of stress-related disease. 
Roman et al (2014) showed that PACAP antagonism could only block the 
sensitized portion of the corticosterone response to the open field maze (OFM). That is, 
PACAP antagonism blunted the corticosterone response only when the animal had been 
previously exposed to chronic stress, and thus, presumably had sensitized BNST 
PACAP signaling/activity. When the animal had only been exposed to an acute stressor 
and ostensibly lacked this sensitized system, PACAP antagonism had no effect on the 
corticosterone response, implicating BNST PACAP signaling as a key mediator of the 
sensitized endocrine response. The current results corroborate and extend these finding 
as a normally subthreshold dose of PACAP following chronic stress was able to 
sensitize both the behavioral and corticosterone response to intra-BNST PACAP, 
arguing for plastic alterations and/or increased signaling as a critical mechanism in 
facilitating the sensitized behavioral and endocrine response following chronic stress; 
but not acute stress. 
We have argued that PACAP is neurotrophic and enhances plasticity, primarily 
within the BNST; moreover, we has suggested that chronic stress promotes stress- and 
anxiety-related affective states by modifying the BNST PACAP system (Hammack and 
May, 2014). This idea is supported by the current study as chronic stress presumably 
altered PACAP signaling (potentially via upregulated PAC1 receptors) within the 
BNST, making it more sensitive to subsequent PACAP release, resulting in a 
 43 
potentiated behavioral and endocrine response. 
Thus, the results of the current study, in combination with our previous findings 
suggest a model (Figure 8) in which the stress-induced plasticity responsible for the 
consequences of repeated stressor exposure result from BNST PACAP/PAC1 system 
interactions with the CRH system to produce both a potentiated behavioral (i.e., 
anxiety) and physiological (i.e., corticosterone) response. Specifically, chronic stress 
appears to upregulate PACAP and PAC1 receptors in the dBNST. The upregulated 
PAC1 receptors could be on CRH neurons, or PACAPergic fiber may interact with 
CRH neurons in the dBNST. This upregulation and signaling within the dBNST results 
in stronger activation of the CRH neurons that project to the nucleus reticularis pontis 
caudalis (Lee and Davis, 1997), resulting in the enhanced anxiety-like startle response. 
Similarly, the increased activation and signaling within the dBNST PACAP and CRH 
neurons could project directly to the PVN to drive the enhanced corticosterone 
response, but more likely, enhanced signaling within dBNST CRH and/or GABAergic 
(and possibly PACAP) projections to the vlBNST results in stronger activation of CRH 
neurons in the PVN and elevated corticosterone release.  
PACAP/PAC1 signaling enhances neuronal activation and when combined with 
the previous results, suggest this system as a key mediator of the stress induced 
plasticity observed in the current study. This could drive subsequent neurochemical 
plasticity effects and resulting plasticity in BNST morphology (i.e., increased dendritic 
branching and overall BNST volume). For instance, we have shown that PACAP may 
be enhancing H-currents, thereby promoting high frequency firing and more 
 44 
peptide release (Lezak and Hammack, unpublished). This could be one mechanism 
through which this system promotes multiple levels of plasticity.  
 
Figure 8: Proposed model of the stress-induced plasticity/alterations within the BNST circuits that 
mediate the downstream nuclei responsible for the sensitized physiological (corticosterone) and 
behavioral (startle) responses following chronic stress.  
The results in aggregate support the hypothesis that repeated stressor exposure 
physically alters the neurochemistry, morphology and physiology associated with 
increases in fear- and anxiety-like behavior to inhibit function within the mPFC and 
facilitate function within BNST. Additionally, they emphasize the importance of altered 
neuropeptide expression in stress-related pathologies, and further implicate the PACAP 
system specifically as a critical system in integrating limbic information within the 
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